Results 31 to 40 of about 7,825,369 (248)

Treatment Patterns and Unmet Need for Patients with Progressive Multiple Sclerosis in the United States: Survey Results from 2016 to 2021

Neurology and Therapy, 2023
Introduction Much of the current literature on treatment patterns and disability progression in multiple sclerosis (MS) does not distinguish between the relapsing–remitting and progressive subtypes (including primary [PPMS] and secondary progressive MS ...
Crystal Watson, Dhanalakshmi Thirumalai, Arie Barlev, Eddie Jones, Sasha Bogdanovich, Kiren Kresa-Reahl   +5 more
doaj   +1 more source

The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report

Consilium Medicum, 2023
Siponimod (Kajendra) is a sphingosine-1-phosphate receptor modulator type 1 and 5 (S1P1,5), the first targeted agent for the treatment of patients with secondary progressive multiple sclerosis, both with and without exacerbations and/or activity ...
Denis S. Korobko, Ivan Ie. Arkhipov, Anna I. Prokaeva, Ekaterina V. Tret'iakova   +3 more
doaj   +1 more source

Consensus for the Early Identification of Secondary Progressive Multiple Sclerosis in Portugal: a Delphi Panel

Acta Médica Portuguesa, 2023
Introduction: Multiple sclerosis is a disease with a heterogeneous evolution. The early identification of secondary progressive multiple sclerosis is a clinical challenge, which would benefit from the definition of biomarkers and diagnostic tools ...
Maria José Sá, Carlos Basílio, Carlos Capela, José João Cerqueira, Irene Mendes, Armando Morganho, João Correia de Sá, Vasco Salgado, Ana Martins Silva, José Vale, Lívia Sousa   +10 more
doaj   +1 more source

Neuroprotection in a Novel Mouse Model of Multiple Sclerosis [PDF]

, 2013
Multiple sclerosis is an immune-mediated, demyelinating and neurodegenerative disease that currently lacks any neuroprotective treatments. Innovative neuroprotective trial designs are required to hasten the translational process of drug development.
Coffey, P, Baker, MD, Coffey Pete, Jackson, SJ, Gavin Giovannoni, Baker David, Samuel J. Jackson (468645), Zubair Ahmed (9352), Jackson Samuel J., Zubair Ahmed, Ahmed, Z, Mark D Baker, Pete Coffey (422262), David Baker, Samuel J Jackson, Gavin Giovannoni (125820), Giovannoni Gavin, Munro Peter, Ahmed Zubair, Pete Coffey, David Baker (11642), Peter Munro (479715), Peter Munro, Lidster Katie, Baker Mark D., Baker, D, Lidster, K, Mark D. Baker (146531), Katie Lidster, Munro, P, Katie Lidster (479714), Giovannoni, G   +31 more
core   +1 more source

Treatment of multiple sclerosis in special populations: The case of refugees [PDF]

, 2020
Multiple sclerosis was long considered a relatively rare entity in the Middle East, but research over the past 10 years and the publication of the Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis guidelines for multiple
Yamout, Bassem I., Zeineddine, Maya M.
core   +1 more source

Can we treat secondary progressive multiple sclerosis now?

Annals of Indian Academy of Neurology, 2019
Secondary progressive multiple sclerosis (SPMS) is characterized by progressive accumulation of disability without intermittent recovery. Treatment of these patients is challenging due to limited understanding of pathogenesis and fewer therapeutic ...
Rohit Bhatia, Nishita Singh
doaj   +1 more source

Assessment of potential cardiotoxic side effects of mitoxantrone in patients with multiple sclerosis [PDF]

, 2005
Previous studies showed that mitoxantrone can reduce disability progression in patients with multiple sclerosis (MS). There is, however, concern that it may cause irreversible cardiomyopathy with reduced left ventricular (LV) ejection fraction (EF) and ...
Zingler, V. C., Hohlfeld, R., Strupp, M., Brandt, T., Jahn, K., Näbauer, M., Gross, A.   +6 more
core   +1 more source

Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis [PDF]

, 2022
Background: Neurogenic lower urinary tract dysfunction (LUTD) results in lower urinary tract symptoms (LUTS) that impact quality of life in people with multiple sclerosis (PwMS).
Saraceno, Taylor J., Gopal, Arpita, Hauser, Stephen L., Polgar-Turcsanyi, Mariann, Chitnis, Tanuja, Cree, Bruce Anthony C.C., Kaplan, Tamara Bockow, Khoury, Samia J., Santaniello, Adam V., El-Ayoubi, Nabil K., Weiner, Howard L., Block, Valerie J., Gomez, Refujia, Consortium, Summit, Suskind, Anne M., Bové, Riley Marie, Zhao, Chao   +16 more
core   +1 more source

Central nervous system macrophages in progressive multiple sclerosis: relationship to neurodegeneration and therapeutics

Journal of Neuroinflammation, 2022
There are over 15 disease-modifying drugs that have been approved over the last 20 years for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited treatment options available for progressive MS.
Emily Kamma, Wendy Lasisi, Cole Libner, Huah Shin Ng, Jason R. Plemel   +4 more
doaj   +1 more source

Predicting the On-Study Relapse Rate for Multiple Sclerosis Patients in Clinical Trials [PDF]

, 2005
Background: The annual relapse rate has been commonly used as a primary efficacy endpoint in phase III multiple sclerosis (MS) clinical trials. The aim of this study was to determine the relative contribution of different possible prognostic factors ...
Chang, C., Polman, Chris, Kappos, L., Polman, C., Held, U., Heigenhauser, L., Shang, C., Heigenhauser, Ludwig, Kappos, Ludwig   +8 more
core   +1 more source